Safety of sugammadex for reversal of neuromuscular block

Figures & data

Figure 1. Schematic structures of sugammadex (Org 25969) and rocuronium. Reproduced with permission from John Wiley and Sons [11]. Copyright © 2002 WILEY‐VCH Verlag GmbH, Weinheim, Fed. Rep. of Germany.

Box 1. Drug summary.

Drug name (generic): Sugammadex

Phase (for indication under discussion): Phase IV

Indication (specific to discussion): Reversal of aminosteroid induced NMB

Pharmacology description/mechanism of action: Cone-shaped encapsulating molecule capable of binding aminosteroidal NMBD with high affinity

Route of administration: Parenteral

Chemical structure: Octakis-(6-deoxy-6-S-mercaptoproprionyl- gamma-CD) sodium salt. See Figure 1.

Pivotal trial(s): Bom et al [11], Gijsenbergh et al [51], Staals et al [58].

Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl. 2002 Jan 18;41(2):266–270.

 PubMed Web of Science ®Google Scholar

Gijsenbergh F, Ramael S, Houwing N, et al. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology. 2005 Oct;103(4):695–703.

 PubMed Web of Science ®Google Scholar

Staals LM, Snoeck MM, Driessen JJ, et al. Reduced clearance of rocuronium and sugammadex in patients with severe to end-stage renal failure: a pharmacokinetic study. Br J Anaesth. 2010 Jan;104(1):31–39.

 PubMed Web of Science ®Google Scholar